New German treatment opens up promising potential for people infected with coronavirus | Health | A must for better health | DW



[ad_1]

German pharmaceutical giant “Merck” and an American laboratory have announced progress in the development of an oral anti-Covid-19 drug, and the drug which is still in trial has shown positive effects on reducing the burden viral.

At the end of January, Merck stopped its development work on two possible vaccines against Covid-19, but is continuing its research on two other treatments for the disease, one of which is the drug “Molnopiravir”, which it is developing in partnership with “Ridgback Bio” from America.

In a meeting with infectious disease specialists on Saturday, the drug’s developers said the drug significantly reduced patients’ viral loads after five days of treatment.

“There is an unmet need for anti-SARS-CoV-2 treatments. These early results encourage us,” said Wendy Pinter, director of drugs at Ridgeback Bio, in a statement.

Merck is also working on a treatment called mk-711. The group said at the end of January that the first results of clinical trials showed a reduction of more than 50% in the risk of death or respiratory failure in hospitalized patients with moderate to severe forms of the emerging corona virus, Covid-19.

PG / HG (AFP)



[ad_2]
Source link